1
|
Ryan F, Cole-Hamilton J, Dandamudi N, Futschik ME, Needham A, Saquib R, Kulasegaran-Shylini R, Blandford E, Kidd M, O'Moore É, Hall I, Sudhanva M, Klapper P, Dodgson A, Moore A, Duke M, Tunkel S, Kenny C, Fowler T. Faster detection of asymptomatic COVID-19 cases among care home staff in England through the combination of SARS-CoV-2 testing technologies. Sci Rep 2024; 14:7475. [PMID: 38553484 PMCID: PMC10980794 DOI: 10.1038/s41598-024-57817-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Accepted: 03/21/2024] [Indexed: 04/02/2024] Open
Abstract
To detect SARS-CoV-2 amongst asymptomatic care home staff in England, a dual-technology weekly testing regime was introduced on 23 December 2020. A lateral flow device (LFD) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) test were taken on the same day (day 0) and a midweek LFD test was taken three to four days later. We evaluated the effectiveness of using dual-technology to detect SARS-CoV-2 between December 2020 to April 2021. Viral concentrations derived from qRT-PCR were used to determine the probable stage of infection and likely level of infectiousness. Day 0 PCR detected 1,493 cases of COVID-19, of which 53% were in the early stages of infection with little to no risk of transmission. Day 0 LFD detected 83% of cases that were highly likely to be infectious. On average, LFD results were received 46.3 h earlier than PCR, enabling removal of likely infectious staff from the workplace quicker than by weekly PCR alone. Demonstrating the rapidity of LFDs to detect highly infectious cases could be combined with the ability of PCR to detect cases in the very early stages of infection. In practice, asymptomatic care home staff were removed from the workplace earlier, breaking potential chains of transmission.
Collapse
Affiliation(s)
- Finola Ryan
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
- King's College Hospital NHS Foundation Trust, London, UK
- Division of Surgery & Interventional Science, University College London, London, UK
| | - Joanna Cole-Hamilton
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Niharika Dandamudi
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Matthias E Futschik
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
- School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, UK
| | - Alexander Needham
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Rida Saquib
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Raghavendran Kulasegaran-Shylini
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Edward Blandford
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | | | - Éamonn O'Moore
- National Health Protection Office, HSE, Dublin, D01 A4A3, Ireland
| | - Ian Hall
- Department of Mathematics, The University of Manchester, Manchester, UK
- Advanced Analytics, Analytics & Data Science, UK Health Security Agency, London, UK
| | - Malur Sudhanva
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
- King's College Hospital NHS Foundation Trust, London, UK
| | - Paul Klapper
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
- Clinical Virology, Division of Evolution, Infections and Genomics, University of Manchester, Manchester, UK
| | - Andrew Dodgson
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Adam Moore
- Operational Policy, UK Health Security Agency, London, UK
| | - Madeleine Duke
- Operational Policy, UK Health Security Agency, London, UK
| | - Sarah Tunkel
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Chris Kenny
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK
| | - Tom Fowler
- Public Health and Clinical Oversight (PHCO), Clinical and Public Health Group, UK Health Security Agency, 10 South Colonade, Canary Wharf, London, E14 4PU, UK.
- Queen Mary University of London William Harvey Research Institute, London, UK.
| |
Collapse
|
2
|
Shansky YD, Yanushevich OO, Gospodarik AV, Maev IV, Krikheli NI, Levchenko OV, Zaborovsky AV, Evdokimov VV, Solodov AA, Bely PA, Andreev DN, Serkina AN, Esiev SS, Komarova AV, Sokolov PS, Fomenko AK, Devkota MK, Tsaregorodtsev SV, Bespyatykh JA. Evaluation of serum and urine biomarkers for severe COVID-19. Front Med (Lausanne) 2024; 11:1357659. [PMID: 38510452 PMCID: PMC10951109 DOI: 10.3389/fmed.2024.1357659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 02/19/2024] [Indexed: 03/22/2024] Open
Abstract
Introduction The new coronavirus disease, COVID-19, poses complex challenges exacerbated by several factors, with respiratory tissue lesions being notably significant among them. Consequently, there is a pressing need to identify informative biological markers that can indicate the severity of the disease. Several studies have highlighted the involvement of proteins such as APOA1, XPNPEP2, ORP150, CUBN, HCII, and CREB3L3 in these respiratory tissue lesions. However, there is a lack of information regarding antibodies to these proteins in the human body, which could potentially serve as valuable diagnostic markers for COVID-19. Simultaneously, it is relevant to select biological fluids that can be obtained without invasive procedures. Urine is one such fluid, but its effect on clinical laboratory analysis is not yet fully understood due to lack of study on its composition. Methods Methods used in this study are as follows: total serum protein analysis; ELISA on moderate and severe COVID-19 patients' serum and urine; bioinformatic methods: ROC analysis, PCA, SVM. Results and discussion The levels of antiAPOA1, antiXPNPEP2, antiORP150, antiCUBN, antiHCII, and antiCREB3L3 exhibit gradual fluctuations ranging from moderate to severe in both the serum and urine of COVID-19 patients. However, the diagnostic value of individual anti-protein antibodies is low, in both blood serum and urine. On the contrary, joint detection of these antibodies in patients' serum significantly increases the diagnostic value as demonstrated by the results of principal component analysis (PCA) and support vector machine (SVM). The non-linear regression model achieved an accuracy of 0.833. Furthermore, PCA aided in identifying serum protein markers that have the greatest impact on patient group discrimination. The study revealed that serum serves as a superior analyte for describing protein quantification due to its consistent composition and lack of organic salts and drug residues, which can otherwise affect protein stability.
Collapse
Affiliation(s)
- Yaroslav D. Shansky
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
| | - Oleg O. Yanushevich
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Alina V. Gospodarik
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
| | - Igor V. Maev
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Natella I. Krikheli
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Oleg V. Levchenko
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Andrew V. Zaborovsky
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Vladimir V. Evdokimov
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Alexander A. Solodov
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Petr A. Bely
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Dmitry N. Andreev
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Anna N. Serkina
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
| | - Sulejman S. Esiev
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
- Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Anastacia V. Komarova
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
- Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Philip S. Sokolov
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Aleksei K. Fomenko
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Mikhail K. Devkota
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Sergei V. Tsaregorodtsev
- Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - Julia A. Bespyatykh
- Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
- Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| |
Collapse
|
3
|
Anand A, Vialard F, Esmail A, Ahmad Khan F, O’Byrne P, Routy JP, Dheda K, Pant Pai N. Self-tests for COVID-19: What is the evidence? A living systematic review and meta-analysis (2020-2023). PLOS GLOBAL PUBLIC HEALTH 2024; 4:e0002336. [PMID: 38324519 PMCID: PMC10849237 DOI: 10.1371/journal.pgph.0002336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Accepted: 01/18/2024] [Indexed: 02/09/2024]
Abstract
COVID-19 self-testing strategy (COVIDST) can rapidly identify symptomatic and asymptomatic SARS-CoV-2-infected individuals and their contacts, potentially reducing transmission. In this living systematic review, we evaluated the evidence for real-world COVIDST performance. Two independent reviewers searched six databases (PubMed, Embase, Web of Science, World Health Organization database, Cochrane COVID-19 registry, Europe PMC) for the period April 1st, 2020, to January 18th, 2023. Data on studies evaluating COVIDST against laboratory-based conventional testing and reported on diagnostic accuracy, feasibility, acceptability, impact, and qualitative outcomes were abstracted. Bivariate random effects meta-analyses of COVIDST accuracy were performed (n = 14). Subgroup analyses (by sampling site, symptomatic/asymptomatic infection, supervised/unsupervised strategy, with/without digital supports) were conducted. Data from 70 included studies, conducted across 25 countries with a median sample size of 817 (range: 28-784,707) were pooled. Specificity and DOR was high overall, irrespective of subgroups (98.37-99.71%). Highest sensitivities were reported for: a) symptomatic individuals (73.91%, 95%CI: 68.41-78.75%; n = 9), b) mid-turbinate nasal samples (77.79%, 95%CI: 56.03-90.59%; n = 14), c) supervised strategy (86.67%, 95%CI: 59.64-96.62%; n = 13), and d) use of digital interventions (70.15%, 95%CI: 50.18-84.63%; n = 14). Lower sensitivity was attributed to absence of symptoms, errors in test conduct and absence of supervision or a digital support. We found no difference in COVIDST sensitivity between delta and omicron pre-dominant period. Digital supports increased confidence in COVIDST reporting and interpretation (n = 16). Overall acceptability was 91.0-98.7% (n = 2) with lower acceptability reported for daily self-testing (39.5-51.1%). Overall feasibility was 69.0-100.0% (n = 5) with lower feasibility (35.9-64.6%) for serial self-testing. COVIDST decreased closures in school, workplace, and social events (n = 4). COVIDST is an effective rapid screening strategy for home-, workplace- or school-based screening, for symptomatic persons, and for preventing transmission during outbreaks. These data will guide COVIDST policy. Our review demonstrates that COVIDST has paved the way for self-testing in pandemics worldwide.
Collapse
Affiliation(s)
- Apoorva Anand
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Fiorella Vialard
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Aliasgar Esmail
- Centre for Lung Infection and Immunity, Division of Pulmonology, UCT Lung Institute and Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa
| | - Faiz Ahmad Khan
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Patrick O’Byrne
- Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada
| | - Jean-Pierre Routy
- Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Keertan Dheda
- Centre for Lung Infection and Immunity, Division of Pulmonology, UCT Lung Institute and Department of Medicine, University of Cape Town, Cape Town, Western Cape, South Africa
| | - Nitika Pant Pai
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Infectious Diseases and Immunity in Global Health, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
4
|
Garg M, Pamme N. Microfluidic (bio)-sensors based on 2-D layered materials. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2022.116839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Iles RK, Iles JK, Zmuidinaite R, Roberts M. A How to Guide: Clinical Population Test Development and Authorization of MALDI-ToF Mass Spectrometry-Based Screening Tests for Viral Infections. Viruses 2022; 14:v14091958. [PMID: 36146765 PMCID: PMC9501081 DOI: 10.3390/v14091958] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Revised: 08/25/2022] [Accepted: 08/31/2022] [Indexed: 01/09/2023] Open
Abstract
Applying MALDI-ToF mass spectrometry as a clinical diagnostic test for viruses is different from that of bacteria, fungi and other micro-organisms. This is because the systems biology of viral infections, the size and chemical nature of specific viral proteins and the mass spectrometry biophysics of how they are quantitated are fundamentally different. The analytical challenges to overcome when developing a clinical MALDI-ToF mass spectrometry tests for a virus, particularly human pathogenic enveloped viruses, are sample enrichment, virus envelope disruption, optimal matrix formulation, optimal MALDI ToF MS performance and optimal spectral data processing/bioinformatics. Primarily, the instrument operating settings have to be optimized to match the nature of the viral specific proteins, which are not compatible with setting established when testing for bacterial and many other micro-organisms. The capacity to be a viral infection clinical diagnostic instrument often stretches current mass spectrometers to their operational design limits. Finally, all the associated procedures, from sample collection to data analytics, for the technique have to meet the legal and operational requirement for often high-throughput clinical testing. Given the newness of the technology, clinical MALDI ToF mass spectrometry does not fit in with standard criteria applied by regulatory authorities whereby numeric outputs are compared directly to similar technology tests that have already been authorized for use. Thus, CLIA laboratory developed test (LDT) criteria have to be applied. This article details our experience of developing a SAR-CoV-2 MALDI-ToF MS test suitable for asymptomatic carrier infection population screening.
Collapse
Affiliation(s)
- Ray K. Iles
- MAP Sciences Ltd., The iLAB, Stannard Way, Priory Business Park, Bedford MK44 3RZ, UK
- Laboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UK
- Correspondence:
| | - Jason K. Iles
- MAP Sciences Ltd., The iLAB, Stannard Way, Priory Business Park, Bedford MK44 3RZ, UK
- Laboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UK
| | - Raminta Zmuidinaite
- MAP Sciences Ltd., The iLAB, Stannard Way, Priory Business Park, Bedford MK44 3RZ, UK
- Laboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UK
| | - Michael Roberts
- Chem Quant Analytical Solutions, LLC, 1093 Investment Blvd, Apex, NC 27502, USA
| |
Collapse
|
6
|
Mei Y, Guo X, Chen Z, Chen Y. An Effective Mechanism for the Early Detection and Containment of Healthcare Worker Infections in the Setting of the COVID-19 Pandemic: A Systematic Review and Meta-Synthesis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:ijerph19105943. [PMID: 35627479 PMCID: PMC9141359 DOI: 10.3390/ijerph19105943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 05/09/2022] [Indexed: 02/04/2023]
Abstract
The COVID-19 pandemic has exposed healthcare workers (HCWs) to serious infection risks. In this context, the proactive monitoring of HCWs is the first step toward reducing intrahospital transmissions and safeguarding the HCW population, as well as reflecting the preparedness and response of the healthcare system. As such, this study systematically reviewed the literature on evidence-based effective monitoring measures for HCWs during the COVID-19 pandemic. This was followed by a meta-synthesis to compile the key findings, thus, providing a clearer overall understanding of the subject. Effective monitoring measures of syndromic surveillance, testing, contact tracing, and exposure management are distilled and further integrated to create a whole-process monitoring workflow framework. Taken together, a mechanism for the early detection and containment of HCW infections is, thus, constituted, providing a composite set of practical recommendations to healthcare facility leadership and policy makers to reduce nosocomial transmission rates while maintaining adequate staff for medical services. In this regard, our study paves the way for future studies aimed at strengthening surveillance capacities and upgrading public health system resilience, in order to respond more efficiently to future pandemic threats.
Collapse
Affiliation(s)
- Yueli Mei
- School of Political Science and Public Administration, East China University of Political Science and Law, Shanghai 201620, China; (Y.M.); (X.G.); (Z.C.)
- Shanghai Jiao Tong University-Yale University Joint Center for Health Policy, Shanghai Jiao Tong University, Shanghai 200030, China
| | - Xiuyun Guo
- School of Political Science and Public Administration, East China University of Political Science and Law, Shanghai 201620, China; (Y.M.); (X.G.); (Z.C.)
| | - Zhihao Chen
- School of Political Science and Public Administration, East China University of Political Science and Law, Shanghai 201620, China; (Y.M.); (X.G.); (Z.C.)
| | - Yingzhi Chen
- School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
- Correspondence: ; Tel.: +86-135-649-90786
| |
Collapse
|
7
|
Pilecky M, Harm S, Bauer C, Zottl J, Emprechtinger R, Eichhorn T, Schildböck C, Ecker M, Willheim M, Weber V, Hartmann J. Performance of lateral flow assays for SARS-CoV-2 compared to RT-qPCR. J Infect 2022; 84:579-613. [PMID: 35033581 PMCID: PMC8758200 DOI: 10.1016/j.jinf.2022.01.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Accepted: 01/08/2022] [Indexed: 12/26/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Michael Ecker
- University Hospital Krems, Clinical Institute for Laboratory Medicine
| | - Martin Willheim
- University Hospital St. Poelten, Clinical Institute for Laboratory Medicine, Karl Landsteiner Private University for Health Sciences, Krems, Austria
| | | | | |
Collapse
|
8
|
Finch LS, Harris A, Lester C, Veal D, Jones K, Fulton J, Jones L, Lee M, Walker T, Rossiter M, Cross M, Kemp S, Fletcher T, Adams ER. Implementation study of SARS-CoV-2 antigen lateral flow tests in men's professional (Premiership) rugby union sports squads in England during the COVID-19 pandemic. J Infect 2021; 84:e3-e5. [PMID: 34974058 PMCID: PMC8717709 DOI: 10.1016/j.jinf.2021.12.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 12/27/2021] [Indexed: 11/20/2022]
Abstract
This study evaluated the validity and utility of antigen-detection rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 in elite sports. The data on utility, ease of use and application for Ag-RDTs as a new testing format were positive from players and staff. This evaluation was limited by the low prevalence of SARS-CoV-2 circulating within the three squads. This study highlights the need for continued service evaluations for SARS-CoV-2 Ag-RDTs in elite sport settings.
Collapse
Affiliation(s)
- Lorna S Finch
- Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK
| | | | - Catherine Lester
- Northampton Rugby Football Club Ltd, Northampton, UK; Centre for Sports and Exercise Medicine, Queen Mary University, London, UK
| | | | | | | | | | - Matt Lee
- Northampton Rugby Football Club Ltd, Northampton, UK
| | | | - Mike Rossiter
- Premiership Rugby, Twickenham, Middlesex, UK; Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK
| | - Matt Cross
- Premiership Rugby, Twickenham, Middlesex, UK
| | - Simon Kemp
- Rugby Football Union, Twickenham, UK; London School of Hygiene and Tropical Medicine, London, UK
| | - Tom Fletcher
- Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
| | - Emily R Adams
- Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK; Mologic, Thurleigh, UK.
| |
Collapse
|
9
|
Heskin J, Pallett SJC, Mughal N, Jones R, Rayment M, Davies GW, Moore LSP. Healthcare worker perceptions of routine asymptomatic SARS-CoV-2 screening using lateral flow assays: A qualitative analysis across two London hospitals. J Infect 2021; 84:e26-e28. [PMID: 34736983 PMCID: PMC8559300 DOI: 10.1016/j.jinf.2021.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 10/23/2021] [Accepted: 10/26/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Joseph Heskin
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom.
| | - Scott J C Pallett
- Centre of Defence Pathology, Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, United Kingdom
| | - Nabeela Mughal
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom; Imperial College Healthcare NHS Trust, North West London Pathology, Fulham Palace Road, London W6 8RF, United Kingdom
| | - Rachael Jones
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom
| | - Michael Rayment
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom
| | - Gary W Davies
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom
| | - Luke S P Moore
- Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 9NH, United Kingdom; Imperial College Healthcare NHS Trust, North West London Pathology, Fulham Palace Road, London W6 8RF, United Kingdom; NIHR Health Protection Research Unit in Healthcare Associated Infections & Antimicrobial Resistance, Imperial College London, Du Cane Road, London, United Kingdom
| |
Collapse
|